Robert Pierce, M.D., Sensei’s Chief R&D Officer, will move to a consulting role as a Science Fellow, effective December 7, 2022, and Edward van der Horst, Ph.D., Sensei’s Senior Vice President, Biologics Discovery & Early Development, has been promoted to Chief Scientific Officer, effective December 7, 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SNSE:
- Sensei Biotherapeutics Provides Update on Strategic Priorities
- Sensei Biotherapeutics management to meet virtually with Oppenheimer
- Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
- Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody
- Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights